Analysis of pituitary gonadotropin concentration in blood serum and immunolocalization and immunoexpression of follicle stimulating hormone and luteinising hormone receptors in ovaries of postmenopausal women

Histology and Histopathology

Volumn 27, Issue 2, 2012, Pages 241-248

  Brodowska, A ^a   Laszczynska, M ^a   Brodowski, J ^a   Masiuk, M ^b   Starczewski, A ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Public Voivodeship Hospital   (Poland)

Author keywords

Epithelial inclusion cysts; FSH and LH receptors; Immunohistochemistry; Pathology; Postmenopausal ovary

Indexed keywords

FOLLITROPIN RECEPTOR; GONADOTROPIN; LUTEINIZING HORMONE RECEPTOR;

AGED; ARTICLE; BIOSYNTHESIS; BLOOD; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUMINESCENCE; METABOLISM; MIDDLE AGED; OVARY; POSTMENOPAUSE;

AGED; FEMALE; GONADOTROPINS, PITUITARY; HUMANS; IMMUNOHISTOCHEMISTRY; LUMINESCENT MEASUREMENTS; MIDDLE AGED; OVARY; POSTMENOPAUSE; RECEPTORS, FSH; RECEPTORS, LH;

EID: 84857764195     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Adashi E.Y. (1994). The climacteric ovary as a functional gonadotropindriven androgen-producing gland. Fertil. Steril. 62, 20-27.
2. Anderson S.M. and Dimitrievich E. (1996). Ovulation induction for infertility: is it safe or not? S. D. J. Med. 49, 419-421.
3. Aoki Y., Kawada N. and Tanaka K. (2000). Early form of ovarian cancer originating in inclusion cysts. A case report. J. Reprod. Med. 45, 159-161.
4. Arslan A.A., Zeleniuch-Jacquotte A., Lundin E., Micheli A., Lukanova A. and Afanasyeva Y. (2003). Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 12, 1531-1535.
5. Auersperg N., Wong A.S., Choi K.C., Kang S.K. and Leung P.C. (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255-288.
6. Blaakaer J. (1997). The pituitary-gonadal function in postmenopausal women with epithelial ovarian tumors. APMIS 74 (Suppl 1), 1-27.
7. Brodowska A., Laszczynska M. and Starczewski A. (2007a). Apoptosis in ovarian cells in postmenopausal women. Folia Histochem. Cytobiol. 45, 99-105.
8. Brodowska A., Laszczynska M., Starczewski A., Karakiewicz B. and Brodowski J. (2007b). The localization of the estrogen receptor Š and its function in the ovaries of postmenopausal women. Folia Histochem. Cytobiol. 45, 325-330.
9. Brodowska A., Laszczynska M., Starczewski A., Brodowski J., Masiuk M. and Domagała W. (2010). Immunohistochemical analysis of steroid receptors in ovaries of postmenopausal women-effects of aging and hormone status. Histol. Histopathol. 25, 1009-1016.
10. Broekmans F.J., Soules M.R. and Fauser B.C. (2009). Ovarian Aging: Mechanisms and Clinical Consequences. Endocr. Rev. 30, 465-493.
11. Buffet N.C. and Bouchard P. (2001). The neuroendocrine regulation of the human ovarian cycle. Chronobiol. Int. 18, 893-919.
12. Burger H.G. (2002). Androgen production in women. Fertil. Steril. 77, Suppl. 4, 33-35.
13. Choi K.C., Kang S.K., Tai C.J., Auersperg N. and Leung P.C. (2002). Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 87, 2245-2253.
14. Choi J.H., Wong A.S., Huang H.F. and Leung P.C. (2007). Gonadotropins and ovarian cancer. Endocr. Rev. 28, 440-461.
15. Chu S., Rushdi S., Zumpe E.T., Mamers P., Healy D.L., Jobling T., Burger H.G. and Fuller P.J. (2002). FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol. Hum. Reprod. 8, 426-433.
16. Chu S., Nishi Y., Yanase T., Nawata H. and Fuller P.J. (2004). Transrepression of estrogen receptor' signaling by nuclear factor-kB in ovarian granulosa cells. Mol. Endocrinol. 18, 1919-1928.
17. Chudecka-Głaz A., Rzepka-Górska I. and Kosmowska B. (2004). Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch. Gynecol. Obstet. 270, 151-156.
18. Cole L.A., Tanaka A., Kim G.S., Park S.Y., Koh M.W., Schwartz P.E., Chambers J.T. and Nam J.H. (1996). Beta-core fragment (betacore/UGF/UGP), a tumor marker: a 7-year report. Gynecol. Oncol. 60, 264-270.
19. Crayford T.J., Campbell S., Bourne T.H., Rawson H.J. and Collins W.P. (2000). Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet 355, 1060-1063.
20. Elder K., Mathews T., Kutner E., Kim E., Espenberg D., Faddy M. and Gosden R. (2008). Impact of gonadotrophin stimulation for assisted reproductive technology on ovarian ageing and menopause. Reprod. Biomed. Online 16, 611-616.
21. Goodman M.T. and Shvestsov Y.B. (2009). Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol. Biomarkers Prev. 18, 132-139.
22. Halperin R., Pansky M., Vaknin Z., Zehavi S., Bukovsky I. and Schneider D. (2003). Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 110, 207-210.
23. Heller D.S, Hameed M. and Baergen R. (2003). Lack of proliferative activity of surface epithelial inclusion cysts of the ovary. Int. J. Gynecol. Cancer 13, 303-307.
24. Helzlsouer K.J., Alberg A.J., Gordon G.B., Longcope C., Bush T.L., Hoffman S.C. and Comstock G.W. (1995). Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274, 1926-1930.
25. Kobayashi H., Sumimoto K., Kitanaka T., Yamada Y., Sado T., Sakata M., Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S. and Terao T. (2008). Ovarian endometrioma-risks factors of ovarian cancer development. Eur. J. Obstet. Gynecol. Reprod. Biol. 138, 187-193.
26. Konishi I., Kuroda H. and Mandai M. (1999). Review: gonadotropins and development of ovarian cancer. Oncology 57, 45-48.
27. Kramer S., Leeker M. and Jager W. (1998). Gonadotropin levels in ovarian cyst fluids: a predictor of malignancy? Int. J. Biol. Markers 13, 165-168.
28. Kuroda H., Mandai M., Konishi I., Yura Y., Tsuruta Y., Hamid A.A., Nanbu K., Matsushita K. and Mori T. (1998). Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG. Int. J. Cancer 18, 571-578.
29. Laszczynska M., Brodowska A., Starczewski A., Masiuk M. and Brodowski J. (2008). Human postmenopausal ovary-hormonally inactive fibrous connective tissue or more? Histol. Histopathol. 23, 219-226.
30. Lu J.J., Zheng Y., Kang X., Yuan J.M., Lauchlan S.C., Pike M.C. and Zheng W. (2000). Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol. Oncol. 79, 158-168.
31. Mandai M., Konishi I., Kuroda H., Fukumoto M., Komatsu T. and Yamamoto S. (1997). Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur. J. Cancer 33, 1501-1507.
32. McSorley M.A., Alberg A.J., Allen D.S., Allen N.E., Brinton L.A., Dorgan J.F., Kaaks R, Rinaldi S. and Helzlsouer K.J. (2009). Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. Int. J. Cancer 125, 674-679.
33. Minegishi T., Kameda T., Hirakawa T., Abe K., Tano M. and Ibuki Y. (2000). Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms. Clin. Cancer Res. 6, 2764-2770.
34. Mittal K.R., Goswami S. and Demopoulos R.I. (1995). Immunohistochemical profile of ovarian inclusion cysts in patients with and without ovarian carcinoma. Histochem. J. 27, 119-122.
35. Nakano R., Shima K., Yamoto M., Kobayashi M., Nishimori K. and Hiraoka J. (1989). Binding sites for gonadotropins in human postmenopausal ovaries. Obstet. Gynecol. 73, 196-200.
36. Parrott J.A., Doraiswamy V., Kim G., Mosher R. and Skinner M.K. (2001). Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol. Cell. Endocrinol. 172, 213-222.
37. Peluso J.J., Steger R.W., Jaszczak S. and Hafez S.E. (1976). Gonadotropin binding sites in human postmenopausal ovaries. Fertil. Steril. 27, 789-795.
38. Rajaniemi H., Kauppila A., Rönnberg L., Selander K. and Pystynen P. (1981). LH(hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet. Gynecol. Scand. 101, (suppl 1), 83-86.
39. Rossing M.A., Daling J.R., Weiss N.S., Moore D.E. and Self S.G. (1994). Ovarian tumors in a cohort of infertile women. N. Engl. J. Med. 331, 771-776.
40. Rzepka-Górska I., Chudecka-Głaz A. and Kosmowska B. (2004). FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr. Relat. Cancer 11, 315-321.
41. Scott M. and McCluggage W.G. (2006). Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data. Histol. Histopathol. 21, 81-92.
42. Scully R.E. (1995). Pathology of ovarian cancer precursors. J. Cell. Biochem. 23, suppl, 208-218.
43. Sherman M.E., Lee J.S, Burks R.T., Struewing J.P., Kurman R.J. and Hartage P. (1999). Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. Int. J. Gynecol. Pathol. 18, 151-157.
44. Skałba P. (2005). Gynecological endocrinology. PZWL, Warszawa. pp 66-74 (in Polish).
45. Speroff L. and Fritz M. (2007). Clinical gynecologic endocrinology and infertility. Medipage, Warszawa, 719-733 (in Polish).
46. Starczewski A., Brodowska A., Laszczynska M. and Piasecka M. (2008). The presence and role of progesterone receptor in the ovaries of postmenopausal women who have not applied hormone replacement therapy. Folia Histochem. Cytobiol. 46, 277-282.
47. Stouffer R.L., Grodin M.S., Davis J.R. and Surwit E.A. (1984). Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers. J. Clin. Endocrinol. Metab. 59, 441-446.
48. Vanderhyden B.C. (2005). Loss of ovarian function and the risk of ovarian cancer. Cell Tissues Res. 322, 117-124.
49. Vartiainen J., Lehtovirta P., Finne P., Stenman U.H. and Alfthan H. (2001). Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer. Int. J. Cancer 95, 313-316.
50. Vartiainen J., Lassus H., Lehtovirta P., Finne P., Alfthan H., Butzow R. and Stenman U.H. (2008). Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma. Int. J. Cancer 1, 2125-2129.
51. Venn A., Watson L., Lumley J., Giles G., King C. and Healy D. (1995). Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet 14, 995-1000.
52. Vihko K.K. (1996). Gonadotropins and ovarian gonadotropin receptors during the perimenopausal transition period. Maturitas 23, 19-22.
53. Wang J., Lin L., Parkash V., Schwartz P.E., Lauchlan S.C. and Zheng W. (2003). Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary Mullerian systems. Int. J. Cancer 103, 328-334.
54. Weiss G., Skurnick J.H., Goldsmith L.T., Santoro N.F. and Park S.J. (2004). Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA 22, 2991-2996.
55. Willemsen W., Kruitwagen R., Bastiaans B., Hanselaar T. and Rolland R. (1993). Ovarian stimulation and granulosa-cell tumour. Lancet 341, 986-988.